tbuckley/cabot-search huggingface dataset:
A systematic review of rehabilitation and exercise recommendations in oncology guidelines
Authors: Nicole L. Stout, Daniel Santa Mina, Kathleen D. Lyons, Karen Robb, Julie K. Silver
Journal: CA A Cancer Journal for Clinicians (2020)

Guidelines promote high quality cancer care. Rehabilitation recommendations in oncology guidelines have not been characterized and may provide insight to improve integration of rehabilitation into oncology care. This report was developed as a part of the World Health Organization (WHO) Rehabilitation 2030 initiative to identify rehabilitation-specific recommendations in guidelines for oncology care. A systematic review of guidelines was conducted. Only guidelines published in English, for adults with cancer, providing recommendations for rehabilitation referral and assessment or interventions between 2009 and 2019 were included. 13840 articles were identified. After duplicates and applied filters, 4897 articles were screened. 69 guidelines were identified with rehabilitation-specific recommendations. Thirty-seven of the 69 guidelines endorsed referral to rehabilitation services but provided no specific recommendations regarding assessment or interventions. Thirty-two of the 69 guidelines met the full inclusion criteria and were assessed using the AGREE II tool. Twenty-one of these guidelines achieved an AGREE II quality score of ≥ 45 and were fully extracted. Guidelines exclusive to pharmacologic interventions and complementary and alternative interventions were excluded. Findings identify guidelines that recommend rehabilitation services across many cancer types and for various consequences of cancer treatment signifying that rehabilitation is a recognized component of oncology care. However, these findings are at odds with clinical reports of low rehabilitation utilization rates suggesting that guideline recommendations may be overlooked. Considering that functional morbidity negatively affects a majority of cancer survivors, improving guideline concordant rehabilitative care could have substantial impact on function and quality of life among cancer survivors.
TCT CONNECT-271 The MeRes-1 Extend Trial: 2-Year Clinical and 6-Month Imaging Outcomes of Thin-Strut Sirolimus-Eluting BRS in Patients With De Novo Coronary Artery Lesions
Authors: Alexandre Abizaid, Sasko Kedev, Rosli Bin Mohd Ali, Teguh Santoso, Angel Cequier, R.J.M. van Geuns, Bernard Chevalier, Farrel Hellig, Ricardo Costa, Yoshinobu Onuma, Jose Costa, Patrick Serruys, Sripal Bangalore
Journal: Journal of the American College of Cardiology (2020)
Abstract 16145: Right Ventricular Dysfunction Should Not Preclude Left Ventricular Assist Device Explantation in Patients Exhibiting Left Ventricular Recovery
Authors: Kiranbir Josan, Anson Cheung, Annemarie Kaan, Andrew Ignaszewski, Jamil Bashir, Mustafa Toma
Journal: Circulation (2011)

Background: A subset of patients implanted with ventricular assist devices (VADs) for decompensated heart failure (HF) will develop enough myocardial recovery to allow explantation of their devices...
Abstract 12274: Human Resistin Induces Mitochondrial Dysfunction via Cyclase-associated Protein 1-mediated Fission
Authors: Han-Mo Yang, Joonoh Kim, Sahmin Lee, Hyo Soo Kim
Journal: Circulation (2019)

Introduction and Hypothesis: Obesity is related to a state of nutrient or energy excess, which requires the downregulation of energy production in order to maintain homeostasis. In human body, mito...
Covid-19 in Sweden and the UK: Risk, the Game of Life
Authors: Des Spence
Journal: BMJ (2020)

Excess death is the only hard number that we have for covid-19.1 In the UK, we are seeing a surge in new cases but not a similar surge in deaths (although there is often a lag of a few weeks).

The key matter, surely, is to establish a true case fatality rate. The reported fatality rate is currently falling, linked to the fact we can now …
TCT CONNECT-427 Initial Experience With the Distal Radial (“Snuffbox”) Access for Coronary Interventions
Authors: Nikola Kos, Mislav Nedic, Ivan Zeljkovic, Marin Pavlov, Tomislav Krcmar, Vjekoslav Radeljic, Sime Manola, Nikola Pavlovic
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-449 Direct Oral Anticoagulants Versus Warfarin Following Left Atrial Appendage Occlusion: A Study-Level Meta-Analysis
Authors: Aravdeep Jhand, Abhishek Thandra, Herbert Aronow, James Freeman, Rahul Sharma, Megan Coylewright, Thomas Porter, Andrew Goldsweig
Journal: Journal of the American College of Cardiology (2020)
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
Authors: P.A. Fasching, T. Link, J. Hauke, F. Seither, C. Jackisch, P. Klare, S. Schmatloch, C. Hanusch, J. Huober, A. Stefek, S. Seiler, W.D. Schmitt, C. Uleer, G. Doering, K. Rhiem, A. Schneeweiss, K. Engels, C. Denkert, R.K. Schmutzler, E. Hahnen, M. Untch, N. Burchardi, J.-U. Blohmer, S. Loibl
Journal: Annals of Oncology (2020)
Natural history and impact of treatment with tafamidis on major cardiovascular outcome‐free survival time in a cohort of patients with transthyretin amyloidosis
Authors: Mélanie Bézard, Mounira Kharoubi, Arnault Galat, Elsa Poullot, Soulef Guendouz, Pascale Fanen, Benoit Funalot, Anissa Moktefi, Jean‐Pascal Lefaucheur, Mukedaisi Abulizi, Jean‐François Deux, Thierry Gendre, Vincent Audard, Khalil el Karoui, Florence Canoui‐Poitrine, Amira Zaroui, Emmanuel Itti, Emmanuel Teiger, Violaine Planté‐Bordeneuve, Silvia Oghina, Thibaud Damy
Journal: European Journal of Heart Failure (2020)
SAT0023 Hla gene polymorphism in psoriatic arthritis (psa)
Authors: S Perrot-Andre, A Ramouneau-Pigot, Y Fontana, J Sany, JF Eliaou, B Combe
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Psoriasis is known to be associated with HLA component (HLA-B*13, B*17, Cw*06 and DRB1*07). However few data exist on HLA association with PsA especially using highly sensitive HLA-Cw, DR and DQ typing methods. <h3>Objectives</h3> The aim of this work was to study the distribution of HLA alleles in PsA patients in comparison with unrelated controls from the same geographic area. <h3>Methods</h3> 69 patients (35 males, 34 females) were included according to modified Avila criteria. A first control group was composed of 328 healthy individuals (random controls: RC). Because alleles at the B and Cw loci are in strong linkage disequilibrium, 60 control individuals matched with patients for HLA-B alleles were selected (matched controls: MC). All the individuals were typed for HLA-A and B by microlymphocytoxicity and for HLA-Cw, DRB1 and DQB1 by PCR-SSP after geno-mic DNA extraction of peripheral blood nucleated cells. The significance of differences in phenotype frequencies was determined by Fischer's exact test. <h3>Results</h3> No significant difference in the HLA-B allele distribution exists between patients and MC. Disease expression of the PsA patients was as follows: skin psoriasis in 100%, axial PsA in 37.7%, asymmetric oligoarthritis in 15.9%, symmetric polyarthritis in 34.8% and asymmetric polyarthritis in 46.4% of the patients. HLA-A*01 (p = 0.0011), B*27 (p = 0.03), B*38 (p = 0.003) and B*57 (p = 0.03) were significantly increased, whereas HLA-A*11 (p = 0.017) and B*18 (p = 0.0019) were significantly decreased in PsA patients compared to RC. 34.4% of the PsA patients carried Cw*0602 compared to 11% in RC (p = 0.003). No difference of DRB1 and DQB1 allele frequencies could be evidenced. When PsA patients and MC were compared no difference of HLA class I and class II allele frequencies was shown except for a significant increase of Cw*0102 in patients (p = 0.0025). Early onset of PsA (as well as psoriasis) was significantly associated with Cw*0602 (p = 0.01) and DRB1*07 (p = 0.03). No association between spondilytis (axial PsA) with and B*27 was observed. Finally, although the sample size is small (10 patients), severe forms of disease were significantly associated with HLA-B*38 (p = 0.0035). <h3>Conclusion</h3> Taken together, these data show that alleles at class I loci are associated with the disease, although it is difficult to assess their specificity to PsA genetic susceptibility. No particular role of the HLA class II region could be demonstrated.
Deep immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized immunotherapy
Authors: Koji Nagaoka, Masataka Shirai, Kiyomi Taniguchi, Akihiro Hosoi, Changbo Sun, Yukari Kobayashi, Kazuhiro Maejima, Masashi Fujita, Hidewaki Nakagawa, Sachiyo Nomura, Kazuhiro Kakimi
Journal: Journal for ImmunoTherapy of Cancer (2020)

Background Although immune checkpoint blockade is effective for several malignancies, a substantial number of patients remain refractory to treatment. The future of immunotherapy will be a personalized approach adapted to each patient’s cancer-immune interactions in the tumor microenvironment (TME) to prevent suppression of antitumor immune responses. To demonstrate the feasibility of this kind of approach, we developed combination therapy for a preclinical model guided by deep immunophenotyping of the TME. Methods Gastric cancer cell lines YTN2 and YTN16 were subcutaneously inoculated into C57BL/6 mice. YTN2 spontaneously regresses, while YTN16 grows progressively. Bulk RNA-Seq, single-cell RNA-Seq (scRNA-Seq) and flow cytometry were performed to investigate the immunological differences in the TME of these tumors. Results Bulk RNA-Seq demonstrated that YTN16 tumor cells produced CCL20 and that CD8 + T cell responses were impaired in these tumors relative to YTN2. We have developed a vertical flow array chip (VFAC) for targeted scRNA-Seq to identify unique subtypes of T cells by employing a panel of genes reflecting T cell phenotypes and functions. CD8 + T cell dysfunction (cytotoxicity, proliferation and the recruitment of interleukin-17 (IL-17)-producing cells into YTN16 tumors) was identified by targeted scRNA-Seq. The presence of IL-17-producing T cells in YTN16 tumors was confirmed by flow cytometry, which also revealed neutrophil infiltration. IL-17 blockade suppressed YTN16 tumor growth, while tumors were rejected by the combination of anti-IL-17 and anti-PD-1 (Programmed cell death protein 1) mAb treatment. Reduced neutrophil activation and enhanced expansion of neoantigen-specific CD8 + T cells were observed in tumors of the mice receiving the combination therapy. Conclusions Deep phenotyping of YTN16 tumors identified a sequence of events on the axis CCL20-&gt;IL-17-producing cells-&gt;IL-17-neutrophil-angiogenesis-&gt;suppression of neoantigen-specific CD8 + T cells which was responsible for the lack of tumor rejection. IL-17 blockade together with anti-PD-1 mAb therapy eradicated these YTN16 tumors. Thus, the deep immunological phenotyping can guide immunotherapy for the tailored treatment of each individual patient’s tumor.
TCT CONNECT-479 Rate of Temporary Pacing in Patients Developing New Left Bundle Branch Block During Transcatheter Aortic Valve Replacement
Authors: Chava Chezar-Azerrad, Vijaywant Brar, Amna Nawaz, Anees Musallam, Brian Case, Charan Yerasi, Nauman Khalid, Evan Shlofmitz, Jaffar Khan, Itsik Ben-Dor, Hayder Hashim, Toby Rogers, Susan O'Donoghue, Lowell Satler, Ron Waksman
Journal: Journal of the American College of Cardiology (2020)
Covid-19 Vaccine Trials and Incarcerated People — The Ethics of Inclusion
Authors: Camila Strassle, E. Jardas, Jorge Ochoa, Benjamin E. Berkman, Marion Danis, Annette Rid, Holly A. Taylor
Journal: New England Journal of Medicine (2020)

Covid-19 Vaccine Trials and Incarcerated People Amid ongoing efforts to reduce the risk of Covid-19 infection in correctional facilities, researchers are considering whether incarcerated people sho...
Risk of osteoporosis and fragility fractures in asthma due to oral and inhaled corticosteroids: two population-based nested case-control studies
Authors: Christos V Chalitsios, Dominick E Shaw, Tricia M McKeever
Journal: Thorax (2020)

Background Inhaled (ICS) and oral (OCS) corticosteroids are used widely in asthma; however, the risk of osteoporosis and fragility fracture (FF) due to corticosteroids in asthma is not well-established. Methods We conducted two nested case-control studies using linked data from the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES) databases. Using an asthma cohort, we separately identified patients with osteoporosis or FF and gender-, age- and practice-matched controls. Conditional logistic regression was used to determine the association between ICS and OCS exposure, and the risk of osteoporosis or FF. The prevalence of patients receiving at least one bisphosphonate was also calculated. Results There was a dose–response relationship between both cumulative dose and number of OCS/ICS prescriptions within the previous year, and risk of osteoporosis or FF. After adjusting for confounders, people receiving more OCS prescriptions (≥9 vs 0) had a 4.50 (95% CI 3.21 to 6.11) and 2.16 (95% CI 1.56 to 3.32) increased risk of osteoporosis and FF, respectively. For ICS (≥11 vs 0) the ORs were 1.60 (95% CI 1.22 to 2.10) and 1.31 (95% CI 1.02 to 1.68). The cumulative dose had a similar impact, with those receiving more OCS or ICS being at greater risk. The prevalence of patients taking ≥9 OCS and at least one bisphosphonate prescription was just 50.6% and 48.4% for osteoporosis and FF, respectively. Conclusions The findings suggest that exposure to OCS or ICS is an independent risk factors for bone health in patients with asthma. Steroid administration at the lowest possible level to maintain asthma control is recommended.
TCT CONNECT-198 A Platelet-Associated Pathophysiologic Mechanism Linking Patent Foramen Ovale and Migraine
Authors: Daniela Trabattoni, Marina Camera, Paola Canzano, Marta Brambilla, Giovanni Teruzzi, Stefano Galli, Paolo Mario Ravagnani, Piero Montorsi, Elena Tremoli, Antonio Bartorelli
Journal: Journal of the American College of Cardiology (2020)
Skin Impedance Measurements with Nanomesh Electrodes for Monitoring Skin Hydration
Authors: Ryotaro Matsukawa, Akihito Miyamoto, Tomoyuki Yokota, Takao Someya
Journal: Advanced Healthcare Materials (2020)

Abstract The importance of continuous monitoring of skin hydration in daily life, to aid in the diagnosis of skin diseases, is rising. Electrodes that can be worn directly on the skin are attracting attention as an effective means. However, they should not inhibit natural water evaporation from the skin and should not cause inflammation or irritation even if they are attached to the body for long periods of time. In this study, nanomesh electrodes that have previously been reported to exhibit high biocompatibility are also found to exhibit high water vapor permeability, resulting in properties that prevent skin dampness. Furthermore, the skin impedance measured using nanomesh electrodes is found to correlate with the hydration level of skin measured using existing medical equipment. This study provides a new approach to measure skin hydration in conditions close to bare skin.
Innovative Tissue‐Engineered Strategies for Osteochondral Defect Repair and Regeneration: Current Progress and Challenges
Authors: Liangbin Zhou, Van Osch GJVM, Jos Malda, Martin J. Stoddart, Yuxiao Lai, R. Geoff Richards, Kevin Ki‐wai Ho, Ling Qin
Journal: Advanced Healthcare Materials (2020)

Abstract Clinical treatments for the repair of osteochondral defects (OCD) are merely palliative, not completely curative, and thus enormously unfulfilled challenges. With the in‐depth studies of biology, medicine, materials, and engineering technology, the conception of OCD repair and regeneration should be renewed. During the past decades, many innovative tissue‐engineered approaches for repairing and regenerating damaged osteochondral units have been widely explored. Various scaffold‐free and scaffold‐based strategies, such as monophasic, biphasic, and currently fabricated multiphasic and gradient architectures have been proposed and evaluated. Meanwhile, progenitor cells and tissue‐specific cells have also been intensively investigated in vivo as well as ex vivo. Concerning bioactive factors and drugs, they have been combined with scaffolds and/or living cells, and even released in a spatiotemporally controlled manner. Although tremendous progress has been achieved, further research and development (R&amp;D) is needed to convert preclinical outcomes into clinical applications. Here, the osteochondral unit structure, its defect classifications, and diagnosis are summarized. Commonly used clinical reparative techniques, tissue‐engineered strategies, emerging 3D‐bioprinting technologies, and the status of their clinical applications are discussed. Existing challenges to translation are also discussed and potential solutions for future R&amp;D directions are proposed.
TCT CONNECT-273 Sirolimus Eluting, Tyrocore, Bioresorbable Vascular Scaffold Implantation in Patients With ST-Segment Elevation Myocardial Infarction: 12 Month Outcomes—FANTOM STEMI Pilot Study
Authors: Lukasz Koltowski, Janusz Kochman, Jeffrey Anderson, Alexandre Abizaid
Journal: Journal of the American College of Cardiology (2020)
Covid-19 in Sweden and UK: medical leadership should energise wider debate
Authors: Andrew Spooner
Journal: BMJ (2020)

Scally’s reported opinion that we have nothing to learn from Sweden is disappointing.1 When cases increased, we locked down the UK for months based on modelling data that are not available to scrutinise. We prioritised the acute care of sick people with one disease over all the other rights of society and generated fear by telling the population they …
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study
Authors: Paul G. Richardson, Hans C. Lee, Al-Ola Abdallah, Adam D. Cohen, Prashant Kapoor, Peter M. Voorhees, Axel Hoos, Karrie Wang, January Baron, Trisha Piontek, Julie Byrne, Scott Richmond, Roxanne C. Jewell, Joanna Opalinska, Ira Gupta, Sagar Lonial
Journal: Blood Cancer Journal (2020)

Abstract DREAMM-2 (NCT03525678) is an ongoing global, open-label, phase 2 study of single-agent belantamab mafodotin (belamaf; GSK2857916), a B-cell maturation antigen-targeting antibody-drug conjugate, in a frozen-liquid presentation in patients with relapsed/refractory multiple myeloma (RRMM). Alongside the main study, following identical inclusion/exclusion criteria, a separate patient cohort was enrolled to receive belamaf in a lyophilised presentation (3.4 mg/kg, every 3 weeks) until disease progression/unacceptable toxicity. Primary outcome was independent review committee-assessed overall response rate (ORR). Twenty-five patients were enrolled; 24 received ≥1 dose of belamaf. As of 31 January 2020, ORR was 52% (95% CI: 31.3–72.2); 24% of patients achieved very good partial response. Median duration of response was 9.0 months (2.8–not reached [NR]); median progression-free survival was 5.7 months (2.2–9.7); median overall survival was not reached (8.7 months–NR). Most common grade 3/4 adverse events were keratopathy (microcyst-like corneal epithelial changes, a pathological finding seen on eye examination [75%]), thrombocytopenia (21%), anaemia (17%), hypercalcaemia and hypophosphatemia (both 13%), neutropenia and blurred vision (both 8%). Pharmacokinetics supported comparability of frozen-liquid and lyophilised presentations. Single-agent belamaf in a lyophilised presentation (intended for future use) showed a deep and durable clinical response and acceptable safety profile in patients with heavily pre-treated RRMM.
TCT CONNECT-408 Prediction of Vessel Rupture Assessed by Optical Coherence Tomography as a Function of Increasing Pressure and Balloon Size in Stent Post-Dilatation for Calcified Coronary Lesions in Ex Vivo and In Silico Experimental Model
Authors: Luis Augusto Dallan, Pengfei Dong, Vladislav Zimin, Juhwan Lee, Yazan Gharaibeh, Gabriel Tensol Rodrigues Pereira, Armando Vergara-Martel, Linxia Gu, David Wilson, Hiram Bezerra
Journal: Journal of the American College of Cardiology (2020)
Abstract GMM-057: A FUNCTIONAL HOMOLOGOUS RECOMBINATION ASSAY PREDICTS PRIMARY CHEMOTHERAPY RESPONSE AND LONG-TERM SURVIVAL IN OVARIAN CANCER PATIENTS
Authors: Manuela Tumiati, Sakari Hietanen, Johanna Hynninen, Elina Pietilä, Anniina Färkkilä, Amjad Alkodsi, Yilin Li, Rainer Lehtonen, Erdogan Pekcan Erkan, Minna M. Tuominen, Kaisa Lehti, Sampsa K. Hautaniemi, Anna Vähärautio, Seija Grénman, Olli Carpén, Liisa Kauppi
Journal: Clinical Cancer Research (2019)

Abstract PURPOSE: Homologous recombination deficiency (HRD) correlates with platinum sensitivity in ovarian cancer patients, which clinically is the most useful predictor of sensitivity to PARPi. For this reason, there is clearly a critical need to identify homologous recombination deficiency (HRD) as early as possible. Currently, HRD is mostly diagnosed by genetic testing, which however fails to identify a large proportion of HR-deficient tumors and predict a patient's response to chemotherapy, thus we aimed to develop an ex vivo functional HRD detection test that could predict both platinum-sensitivity and patient eligibility to targeted drug treatments. METHODS: We obtained a functional HR score by quantifying homologous recombination (HR) repair after ionizing radiation-induced DNA damage in primary ovarian cancer samples (n=32). Samples clustered in 3 categories: HR-deficient, HR-low and HR-proficient. We analysed the HR score association with platinum sensitivity and treatment response, platinum-free interval (PFI) and overall survival (OS), and compared it with other clinical parameters. In parallel, we performed whole-genome sequencing and targeted DNA-sequencing of HR genes to assess if functional HRD can be predicted by currently offered genetic screening. RESULTS: Low HR scores predicted primary platinum sensitivity with high statistical significance (p=0.0103), associated with longer PFI (HR-deficient vs HR-proficient: 531 vs 53 days), and significantly correlated with improved OS (HR score &amp;lt;35 vs ≥35, hazard ratio=0.08, p=0.0116). At the genomic level, we identified a few unclear mutations in HR genes and the mutational signature associated with HRD, but, overall, genetic screening failed to predict functional HRD. CONCLUSIONS: We developed an ex vivo assay that detects tumor functional HRD and an HR score able to predict platinum sensitivity, which holds the clinically relevant potential to become the routine companion diagnostic in the management of ovarian cancer patients. Citation Format: Manuela Tumiati, Sakari Hietanen, Johanna Hynninen, Elina Pietilä, Anniina Färkkilä, Amjad Alkodsi, Yilin Li, Rainer Lehtonen, Erdogan Pekcan Erkan, Minna M. Tuominen, Kaisa Lehti, Sampsa K. Hautaniemi, Anna Vähärautio, Seija Grénman, Olli Carpén, and Liisa Kauppi. A FUNCTIONAL HOMOLOGOUS RECOMBINATION ASSAY PREDICTS PRIMARY CHEMOTHERAPY RESPONSE AND LONG-TERM SURVIVAL IN OVARIAN CANCER PATIENTS [abstract]. In: Proceedings of the 12th Biennial Ovarian Cancer Research Symposium; Sep 13-15, 2018; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2019;25(22 Suppl):Abstract nr GMM-057.